Table 1.
Selected ongoing clinical trials with current status and phase for trials related to neuroinflammation and acute cerebral ischemia.
| NCT number | Study title | Summary//Status | Location and phase |
|---|---|---|---|
| NCT05277129 | The Immune Response to Stroke | Observational study analyzing B and T Cell response after stroke and correlating with clinical outcome. // Recruiting | Akershus University Hospital, Lørenskog, Norway |
| NCT04852445 | The Temporal Cellular Landscape of the Adaptive Immune System in Patients With Acute Stroke | Case Control Study seeking to determine by peripheral blood samples if patients that experience an increase in anti inflammatory Treg cells (CD4+, CD25, +FoxP3+, “brain” Treg) after stroke have improved clinical outcomes. // Recruiting. | Academisch Medisch Centrum—Universiteit van Amsterdam, Netherlands |
| NCT06248242 | Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol | RCT prospective cohort study to assess effect of a free radical scavanger (Edaravone) and inflammatory cytokine inhibitor (Dexborneol) on outcomes post stroke. // Recruiting | The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China |
| NCT03662750 | Inflammatory faCtors AfteR acUte Ischemic Stroke (ICARUS) | Single-centre hospital-based cohort using serial TSPO-PET imaging, immune cell profiling to assess the degree of microglial activation and coorelate that with circulating immune bio markers. // Recruiting | Imperial College London; Institute for Stroke and Dementia Research, Munich, Germany |
| NCT04675762 | Combination Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke | RCT assess the efficacy of an Immune Modulator Fingolimod (sphingosine-1-phosphate receptor modulator) is a beneficial additional treatment to alteplase and thrombectomy. // Recruiting | Zhejiang University; Hangzhou, China |
| NCT04321512 | Study of Circulating Monocytes in Patients With Ischemic Vascular Disease | Prospective observational study to determine the levels of P2X4 monocytes, Flt-1/VEGFR-1 and CD13 monocytes, thought to be linked to post ischemic immune meditated injury, in stroke and heart attack patients. // Recruiting | University of Connecticut, CT, USA |
| NCT05880524 | Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD) (ReSCInD) | Randomized, placebo-controlled single-blinded, single-center trial test the hypothesis that DNase 1 administration leads to a reduction in systemic immune response measured in patients after acute ischemic stroke compared to control treatment. // Not yet recruiting. | University of Munich, Germany Phase 2 |
NCT, national clinical trials registry number; RCT, randomized control trial.